Selected article for: "heart failure and mortality risk"
Author: Jennifer C.E Lane; James Weaver; Kristin Kostka; Talita Duarte-Salles; Maria Tereza F. Abrahao; Heba Alghoul; Osaid Alser; Thamir M Alshammari; Patricia Biedermann; Edward Burn; Paula Casajust; Mitch Conover; Aedin C. Culhane; Alexander Davydov; Scott L. DuVall; Dmitry Dymshyts; Sergio Fernández Bertolín; Kristina Fišter; Jill Hardin; Laura Hester; George Hripcsak; Seamus Kent; Sajan Khosla; Spyros Kolovos; Christophe G. Lambert; Johan ver der Lei; Ajit A. Londhe; Kristine E. Lynch; Rupa Makadia; Andrea V. Margulis; Michael E. Matheny; Paras Mehta; Daniel R. Morales; Henry Morgan-Stewart; Mees Mosseveld; Danielle Newby; Fredrik Nyberg; Anna Ostropolets; Rae Woong Park; Albert Prats-Uribe; Gowtham A. Rao; Christian Reich; Jenna Reps; Peter Rijnbeek; Selva Muthu Kumaran Sathappan; Martijn Schuemie; Sarah Seager; Anthony Sena; Azza Shoaibi; Matthew Spotnitz; Marc A. Suchard; Joel Swerdel; Carmen Olga Torre; David Vizcaya; Haini Wen; Marcel de Wilde; Seng Chan You; Lin Zhang; Oleg Zhuk; Patrick Ryan; Daniel Prieto-Alhambra
Title: Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
  • Document date: 2020_4_10
    • ID: 2hbcbvt6_68
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint Our results suggest that long-term use of HCQ leads to an increased risk of cardiovascular mortality, with no observable excess risk of major cardiovascular events or diagnosed bradycardia. Considering the current evidence, this may relate to cumulative effects of HCQ leading to an increased risk of QT lengthening or relate to the moderately increased risk of angina and h.....
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint Our results suggest that long-term use of HCQ leads to an increased risk of cardiovascular mortality, with no observable excess risk of major cardiovascular events or diagnosed bradycardia. Considering the current evidence, this may relate to cumulative effects of HCQ leading to an increased risk of QT lengthening or relate to the moderately increased risk of angina and heart failure seen. However, as the strong association observed with cardiovascular death is not observed with diagnosed arrhythmia or bradycardia in this study, sudden cardiovascular death here is more likely due to QT lengthening and undetected and/or sudden torsade-de-pointes. Although long-term treatment with HCQ is not expected for the management of COVID-19, some research suggests that higher doses as prescribed for COVID-19

    Search related documents:
    Co phrase search for related documents
    • cardiovascular death and excess risk: 1, 2, 3, 4
    • cardiovascular death and heart angina failure: 1, 2, 3, 4
    • cardiovascular death and high dose: 1
    • cardiovascular death and increase risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • cardiovascular death and long term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • cardiovascular death and long term treatment: 1, 2, 3, 4
    • cardiovascular death and major cardiovascular event: 1, 2, 3, 4, 5, 6, 7
    • cardiovascular death and QT lengthening: 1
    • cardiovascular death and sudden cardiovascular death: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • cardiovascular event and excess risk: 1
    • cardiovascular event and high dose: 1, 2, 3
    • cardiovascular event and increase risk: 1, 2, 3, 4
    • cardiovascular event and long term: 1, 2, 3
    • cardiovascular event and major cardiovascular event: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cardiovascular mortality and current evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • cardiovascular mortality and excess risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • cardiovascular mortality and HCQ long term treatment: 1, 2
    • cardiovascular mortality and heart angina failure: 1, 2, 3, 4, 5, 6, 7
    • cardiovascular mortality and high dose: 1, 2, 3, 4